Showing 2221-2230 of 3039 results for "".
- AptarGroup Highlights New “Beat the Blink” Technologyhttps://modernod.com/news/aptargroup-highlights-new-beat-the-blink-technology/2485307/AptarGroup shared an overview of its portfolio of eye care solutions, including 'Beat the Blink,' a new eye care delivery system designed to improve dosing accuracy and enhance the patient experience by “beating the blink” reflex. The technology is currently part of
- Everest Medicines Expands into Ophthalmology with Licensing Agreement for Retinal Disease Candidate in Asiahttps://modernod.com/news/everest-medicines-expands-into-ophthalmology-with-licensing-agreement-for-retinal-disease-candidate-in-asia/2484302/Everest Medicines announced it has entered into an exclusive licensing agreement with Visara, a subsidiary of NovaBridge Biosciences to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and select Southeast Asian countri
- Locus Biosciences Announces Collaboration with Viatris to Develop Antibacterial Therapies for Ophthalmic Infectionshttps://modernod.com/news/locus-biosciences-announces-collaboration-with-viatris-to-develop-antibacterial-therapies-for-ophthalmic-infections/2484292/Locus Biosciences announced a research collaboration agreement with Viatris to develop novel engineered bacteriophage therapies targeting ophthalmic bacterial infections. While financial terms of the deal were not disc
- SpyGlass Pharma Announces Promising 24-Month Interim Results from First-in-Human Trial of BIM-IOL Systemhttps://modernod.com/news/spyglass-pharma-announces-promising-24-month-interim-results-from-first-in-human-trial-of-bim-iol-system/2484179/SpyGlass Pharma announced interim 24-month data from its first-in-human clinical trial evaluating the Bimatoprost Drug Pad-IOL System (BIM-IOL System). This technology integrates proprietary non-bioerodible drug pads with SpyGlass Pharma’s IOL, designed
- Johnson & Johnson Marks 100,000 US Implants of Tecnis Odyssey IOL; Showcases Innovations at AAO 2025https://modernod.com/news/johnson-johnson-marks-100000-us-implants-of-tecnis-odyssey-iol-and-showcases-innovations-at-aao-2025/2484177/Johnson & Johnson announced that its Tecnis Odyssey IOL has now been implanted in 100,000 eyes since its 2024 launch. The company will highlight this milestone alongside new data presentations and technology showcases
- Heidelberg and NetraMind Collaborate to Deliver AI-Powered Choroid Analysis on AppWay Marketplacehttps://modernod.com/news/heidelberg-and-netramind-collaborate-to-deliver-ai-powered-choroid-analysis-on-appway-marketplace/2484166/Heidelberg Engineering announced a new collaboration with NetraMind Innovations, an AI-driven image analysis software company founded by retinal specialists and machine learning engineers. Their new application, NMI-ChoroidAI,* is now available via the Heidelb
- American Academy of Optometry Announces 2025 Award Recipientshttps://modernod.com/news/american-academy-of-optometry-announces-2025-award-recipients/2484131/Each year, the American Academy of Optometry (AAOpt) recognizes distinguished individuals whose contributions advance the profession of optometry and vision science. The Academy’s awardees are nominated by fellows and are based on contributions made in t
- FDA Clears IND for Opus Genetics’ OPGx-BEST1 Gene Therapy Candidatehttps://modernod.com/news/fda-clears-ind-for-opus-genetics-opgx-best1-gene-therapy-candidate/2484123/Opus Genetics announced that the FDA has accepted its investigational new drug (IND) application for OPGx-BEST1, a gene therapy for the treatment of bestrophin-1 (BEST1)-related inherited retinal diseases (IRDs). The company now plans to initiate a Phase 1/2 clinical trial in the second
- Myra Vision Secures FDA Approval to Initiate US-Based IDE Study in Glaucomahttps://modernod.com/news/myra-vision-secures-fda-approval-to-initiate-us-based-ide-study-in-glaucoma/2482933/Myra Vision announced today that the FDA has issued a conditional approval letter for its investigational device exemption (IDE) application, allowing the company to initiate the ADAPT study. The prospective, nonr
- Ocular Therapeutix Secures FDA Special Protocol Assessment for NPDR Trial of Axpaxlihttps://modernod.com/news/ocular-therapeutix-secures-fda-special-protocol-assessment-for-npdr-trial-of-axpaxli/2482930/Ocular Therapeutix has received written agreement from the FDA under a Special Protocol Assessment (SPA) for the registrational trial design of Axpaxli (OTX-TKI) for the treatment of nonproliferative diabetic retinopathy (NPDR).